Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - Ludvik, Bernhard; Giorgino, Francesco; Jódar, Esteban; Frias, Juan P; Fernández Landó, Laura; Brown, Katelyn; Bray, Ross; Rodríguez, Ángel (The Lancet (British edition), 2021)
Keywords: Adverse events; Agonists; Algorithms; Antidiabetics; Appetite loss; Blood glucose; Blood pressure; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetic retinopathy; Diarrhea; Dosage; Drug dosages; GIP protein; GLP-1 receptor agonists; Glucagon; Glucose; Hemoglobin; Hyperglycemia; Hypoglycemia; Inhibitors; Injection; Insulin; Interactive systems; International organizations; Metabolism; Metformin; Nausea; Pancreatitis; Patients; Polypeptides; Receptors; Safety; Safety analysis; Vomiting; United States--US